Panacea Biotech has bagged the registration, production and marketing rights of the anti-anthrax vaccine developed by the Centre for Biotechnology in the Jawaharlal Nehru University (JNU). It is ...

Panacea Biotec will own 14.5% of the firm, while PharmAthene gains rights to future distribution of Panacea Biotec’s products. Panacea Biotec will purchase PharmAthene shares for $13.1 million ...

Panacea Biotec to Make a $13.1 Million Strategic Investment in PharmAthene ANNAPOLIS, Md., Sept. 30 -- PharmAthene, Inc. (Amex: PIP - News), a biodefense company developing medical countermeasures ...

Panacea Biotec Ltd., incorporated in 1984, is a small-cap company with a market capitalization of Rs 2,653.69 crore, operating in the pharmaceuticals sector.

Panacea Biotec has entered into an agreement with Laboratorios Clausen of Uruguay for grant of non-exclusive marketing rights of the company's immunosuppressant drug `Tacrolimus (Pangraph)' for a ...

Panacea Biotec is India's leading research-based health management company with established research, manufacturing and marketing capabilities. Panacea Biotec is the 2nd largest vaccine producer ...

Under the terms of the agreement, Panacea Biotec shall receive an upfront research fee on signing as well as a milestone payment on approval of the product by FDA ...

Panacea Biotec locked in upper circuit of 10 per cent on Tuesday after the company informed bourses that it has introduced indigenously developed high quality antidiabetic drug.

Panacea Biotec shares were up 0.7 percent at Rs 154.25 in early trade on October 30 after the company launched injectable suspension to treat breast and lung cancer. The company's material wholly ...

MUMBAI, March 3 (Reuters) - Panacea Biotec Ltd on Thursday said it has signed a non-exclusive marketing agreement with Uruguay-based Laboratorios Clausen S.A. The agreement will allow to ...